Liminatus Pharma (LIMN) Prepaid Assets (2024 - 2026)

Liminatus Pharma (LIMN) posted Prepaid Assets of $870872.0 for Q1 2026, up 434.54% sequentially from $162919.0 in Q4 2025.

Liminatus Pharma (LIMN) Prepaid Assets (2024 - 2026) Analysis & Trends

Liminatus Pharma has reported Prepaid Assets for 3 years, with the latest figure at $870872.0 in Q1 2026.

Quarterly Prepaid Assets changed N/A year-over-year to $870872.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $870872.0 (changed N/A YoY) and the FY2025 annual result came in at $162919.0, up 4.77% from the prior year.
Prepaid Assets climbed to $870872.0 in Q1 2026 per LIMN's latest filing, from $162919.0 in the prior quarter.
Over five years, Prepaid Assets peaked at $870872.0 in Q1 2026 and troughed at $155501.0 in Q4 2024.
A 3-year average of $422449.2 and a median of $444086.0 in 2025 frame the typical range for Prepaid Assets.
The widest YoY moves for Prepaid Assets: up 4.77% in 2025, down 4.77% in 2025.
Over 3 years, Prepaid Assets stood at $155501.0 in 2024, then climbed by 4.77% to $162919.0 in 2025, then soared by 434.54% to $870872.0 in 2026.
According to Business Quant data, Prepaid Assets over the past three periods registered $870872.0, $162919.0, and $478868.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Liminatus Pharma	256.03 Mn	256.03 Mn	-

Download Data